Prevalence of Major Depression Among Immigrants in Santiago, Chile

Major Depressive Disorder Clinical Trial

— STRING  

Official title:

The Santiago Immigrant Wellbeing Study (STRING): Prevalence of Mood Disorders Among Immigrants in Santiago, Chile

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04114565
• Other study ID #: 17051004
• Secondary ID: 96875479
• Status: Completed
• Start date: July 29, 2019
• Est. completion date: June 30, 2020

Study information

• Verified date: July 2020
• Source: Pontificia Universidad Catolica de Chile
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The general aim of this study is to explore the prevalence of major depressive disorder and the use of mental health services in the immigrant populations in the Metropolitan Region of Santiago, Chile.

The hypotheses are:

1. A healthy immigrant effect will be observed in the studied population by which their prevalence of major depressive disorder will be lower than the prevalence in the general Chilean population.

2. A significant association will be observed between the loss of socio-economic position after migration and a greater probability of major depressive disorder.

3. A significant association will be observed between the report of victimization experience(s) in the previous year and a greater probability of major depressive disorder.

4. A significant association will be observed between financial difficulties and a greater probability of major depressive disorder.

The sampling framework of the Chilean National Institute of Statistics (INE) from the 2016 Census will be used for the purpose of this research. The sampling units are as follows:

1. Primary sampling units (PSUs): conglomerates or groups of adjoining houses, organized in spatial blocks (200 households on average)

2. Secondary sampling units (SSUs): individual households within each of the conglomerates selected in the first stage

3. Final sampling units: persons meeting the study's inclusion criteria Multi-stage random probability sampling involving a 3-stage sampling design will be used - first, the sampling of the primary sampling units (PSUs); second, the sampling of households within the selected PSUs and finally, the random sampling of a household member.

Participants (n=1,100) will then take part in a 45-minute interview. This interview will be a household survey using the modular version of the Composite International Diagnostic Interview (WHO-CIDI) looking at exploring a broad spectrum of factors traditionally associated with increased risk of affective disorders:

1. Sociodemographics

2. Finance

3. Variation in socioeconomic position

4. Experience of victimization

5. Discrimination

6. Experience of childhood adversity

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1092
• Est. completion date: June 30, 2020
• Est. primary completion date: November 30, 2019
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Country of birth other than Chile

• Time since arrival to Chile: 3 months

Exclusion Criteria:

• Unable to understand Spanish

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Locations

Country	Name	City	State
Chile	Pontificia Universidad Catolica de Chile	Santiago	RM

Sponsors (2)

Lead Sponsor	Collaborator
Pontificia Universidad Catolica de Chile	Fondo Nacional de Desarrollo Científico y Tecnológico, Chile

Country where clinical trial is conducted

Chile, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Major Depressive Disorder	Assessed using the World Health Organisation Composite International Diagnostic Interview (WHO-CIDI)	baseline
Primary	Any affective/mood disorder	Assessed using the WHO-CIDI	baseline
Primary	Suicidal ideation, plans and attempts	Assessed using the WHO-CIDI	baseline
Primary	Depressive symptoms	Assessed using the nine-item Patient Health Questionnaire (PHQ-9).; The PHQ-9 score can range from 0 to 27, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-19 Moderate to Severe; 20-27 Severe.	baseline
Primary	Anxiety symptoms	Assessed using the Generalized Anxiety Disorder 7-item scale (GAD-7).; The GAD-7 score can range from 0 to 21, with the following severity scores: 0-4 None; 5-9 Mild; 10-14 Moderate; 15-21 Severe.	baseline
Secondary	Mental wellbeing	Assessed using the Warwick-Edinburgh Mental Well-Being Scale (WEMWBS).; The 14 Items are scored on a range from 1 to 5, providing a total score between 14 and 70 with higher values indicating higher mental well-being.	baseline
Secondary	Mental health service use	Assessed using items of the Services Module of the WHO-CIDI	baseline
Secondary	Hazardous/harmful drinking	Assessed using the Alcohol Use Disorders Identification Test (AUDIT)	baseline

External Links

•   ISRCTN registry